REFERENCES
- Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617, [INFOTRIEVE], [CSA]
- Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226–1237, [INFOTRIEVE], [CSA]
- Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–2138, [INFOTRIEVE], [CSA]
- Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function. Kidney Int 1993; 44: 860–866, [INFOTRIEVE], [CSA]
- Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995; 10: 149–156, [INFOTRIEVE], [CSA]
- Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate—phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104–115, [INFOTRIEVE], [CSA]
- Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245–252, [INFOTRIEVE], [CROSSREF], [CSA]
- Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694–701, [INFOTRIEVE], [CSA]
- Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914–1926, [INFOTRIEVE], [CROSSREF], [CSA]
- Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294–2302, [INFOTRIEVE], [CROSSREF], [CSA]
- Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of a dynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065–1072, [INFOTRIEVE], [CSA]
- Urena P, Hruby M, Ferreira A, Ang KS, De Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506–512, [INFOTRIEVE], [CSA]
- Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000; 13: 437–443, [INFOTRIEVE], [CSA]
- Rodriguez-Perez JC, Plaza C, Torres A, et al. Low turnover bone disease is the more common form of bone disease in CAPD patients. Adv Perit Dial 1992; 8: 376–380, [INFOTRIEVE], [CSA]
- Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245–1254, [INFOTRIEVE], [CROSSREF], [CSA]
- Avram MM, Sreedhara R, Avram DK, Muchnick RA, Fein P. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. Am J Kidney Dis 1996; 28: 924–930, [INFOTRIEVE], [CSA]
- Izumi M, Shirai K, Ito K, et al. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. Ther Apher Dial 2005; 9: 24–31, [INFOTRIEVE], [CROSSREF], [CSA]
- U.S. Renal Data System. USRDS 1999 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md 1999
- Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphate binders or sevelamer. J Heart Valve Dis 2004; 13: 134–141, [INFOTRIEVE], [CSA]
- Geoffrey AB, David MS, James E, et al. Effect of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815–1824, [CROSSREF], [CSA]
- Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000; 54: 334–341, [INFOTRIEVE], [CSA]